lasofoxifene

Manufacturer is seeking FDA approval Feb 2010. Indications: - osteoporosis - may lower risk for a) estrogen-receptor positive breast cancer (HR, 0.19) b) coronary heart disease events (HR, 0.68) c) stroke (HR, 0.64) Dosage: - 0.25 mg or 0.5 mg P QD Adverse effects: - venous thromboembolic events (HR, 2) - pulmonary embolism (HR, > 4) - endometrial polyps & hypertrophy

References

- Cummings SR et al Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010 Feb 25; 362:686. PMID: 20181970 - Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med 2010 Feb 25; 362:752 PMID: 20181977